Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis

ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.

Saved in:
Bibliographic Details
Main Authors: Branco,Luciana Prats, Adoni,Tarso, Apostolos-Pereira,Samira Luisa, Brooks,Joseph Bruno Bidin, Correa,Eber Castro, Damasceno,Carlos Augusto, Eboni,Audred Cristina Biondo, Fezer,Leticia, Gama,Paulo Diniz da, Goncalves,Marcus Vinicius Magno, Gomes,Sidney, Grzesiuk,Anderson Kuntz, Mendes,Maria Fernanda, Morales,Rogerio Rizo, Muniz,Andre, Parolin,Monica Fiuza Koncke, Pimentel,Maria Lucia Vellutini, Ribeiro,Marlise de Castro, Santos,Gutemberg Augusto Cruz dos, Sato,Henry Koiti, Scherpenhuijzen,Simone Batista, Scorcine,Claudio, Siquineli,Fabio, Sousa,Nise Alexandra de Carvalho, Varela,Daniel Lima, Winckler,Tereza Cristina Avila, Fragoso,Yara Dadalti
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2018
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000900588
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2018000900588
record_format ojs
spelling oai:scielo:S0004-282X20180009005882018-10-10Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosisBranco,Luciana PratsAdoni,TarsoApostolos-Pereira,Samira LuisaBrooks,Joseph Bruno BidinCorrea,Eber CastroDamasceno,Carlos AugustoEboni,Audred Cristina BiondoFezer,LeticiaGama,Paulo Diniz daGoncalves,Marcus Vinicius MagnoGomes,SidneyGrzesiuk,Anderson KuntzMendes,Maria FernandaMorales,Rogerio RizoMuniz,AndreParolin,Monica Fiuza KonckePimentel,Maria Lucia VellutiniRibeiro,Marlise de CastroSantos,Gutemberg Augusto Cruz dosSato,Henry KoitiScherpenhuijzen,Simone BatistaScorcine,ClaudioSiquineli,FabioSousa,Nise Alexandra de CarvalhoVarela,Daniel LimaWinckler,Tereza Cristina AvilaFragoso,Yara Dadalti multiple sclerosis leukoencephalopathy, progressive multifocal JC virus natalizumab ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.76 n.9 20182018-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000900588en10.1590/0004-282x20180083
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Branco,Luciana Prats
Adoni,Tarso
Apostolos-Pereira,Samira Luisa
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Carlos Augusto
Eboni,Audred Cristina Biondo
Fezer,Leticia
Gama,Paulo Diniz da
Goncalves,Marcus Vinicius Magno
Gomes,Sidney
Grzesiuk,Anderson Kuntz
Mendes,Maria Fernanda
Morales,Rogerio Rizo
Muniz,Andre
Parolin,Monica Fiuza Koncke
Pimentel,Maria Lucia Vellutini
Ribeiro,Marlise de Castro
Santos,Gutemberg Augusto Cruz dos
Sato,Henry Koiti
Scherpenhuijzen,Simone Batista
Scorcine,Claudio
Siquineli,Fabio
Sousa,Nise Alexandra de Carvalho
Varela,Daniel Lima
Winckler,Tereza Cristina Avila
Fragoso,Yara Dadalti
spellingShingle Branco,Luciana Prats
Adoni,Tarso
Apostolos-Pereira,Samira Luisa
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Carlos Augusto
Eboni,Audred Cristina Biondo
Fezer,Leticia
Gama,Paulo Diniz da
Goncalves,Marcus Vinicius Magno
Gomes,Sidney
Grzesiuk,Anderson Kuntz
Mendes,Maria Fernanda
Morales,Rogerio Rizo
Muniz,Andre
Parolin,Monica Fiuza Koncke
Pimentel,Maria Lucia Vellutini
Ribeiro,Marlise de Castro
Santos,Gutemberg Augusto Cruz dos
Sato,Henry Koiti
Scherpenhuijzen,Simone Batista
Scorcine,Claudio
Siquineli,Fabio
Sousa,Nise Alexandra de Carvalho
Varela,Daniel Lima
Winckler,Tereza Cristina Avila
Fragoso,Yara Dadalti
Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
author_facet Branco,Luciana Prats
Adoni,Tarso
Apostolos-Pereira,Samira Luisa
Brooks,Joseph Bruno Bidin
Correa,Eber Castro
Damasceno,Carlos Augusto
Eboni,Audred Cristina Biondo
Fezer,Leticia
Gama,Paulo Diniz da
Goncalves,Marcus Vinicius Magno
Gomes,Sidney
Grzesiuk,Anderson Kuntz
Mendes,Maria Fernanda
Morales,Rogerio Rizo
Muniz,Andre
Parolin,Monica Fiuza Koncke
Pimentel,Maria Lucia Vellutini
Ribeiro,Marlise de Castro
Santos,Gutemberg Augusto Cruz dos
Sato,Henry Koiti
Scherpenhuijzen,Simone Batista
Scorcine,Claudio
Siquineli,Fabio
Sousa,Nise Alexandra de Carvalho
Varela,Daniel Lima
Winckler,Tereza Cristina Avila
Fragoso,Yara Dadalti
author_sort Branco,Luciana Prats
title Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
title_short Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
title_full Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
title_fullStr Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
title_full_unstemmed Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
title_sort serological profile of john cunningham virus (jcv) in patients with multiple sclerosis
description ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2018
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018000900588
work_keys_str_mv AT brancolucianaprats serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT adonitarso serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT apostolospereirasamiraluisa serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT brooksjosephbrunobidin serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT correaebercastro serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT damascenocarlosaugusto serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT eboniaudredcristinabiondo serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT fezerleticia serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT gamapaulodinizda serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT goncalvesmarcusviniciusmagno serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT gomessidney serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT grzesiukandersonkuntz serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT mendesmariafernanda serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT moralesrogeriorizo serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT munizandre serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT parolinmonicafiuzakoncke serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT pimentelmarialuciavellutini serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT ribeiromarlisedecastro serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT santosgutembergaugustocruzdos serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT satohenrykoiti serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT scherpenhuijzensimonebatista serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT scorcineclaudio serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT siquinelifabio serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT sousanisealexandradecarvalho serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT vareladaniellima serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT wincklerterezacristinaavila serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
AT fragosoyaradadalti serologicalprofileofjohncunninghamvirusjcvinpatientswithmultiplesclerosis
_version_ 1756374755399696384